New ADC Shrinks HER2-Positive Tumors.
A phase I trial reported positive results for an antibody-drug conjugate that targets HER2-positive tumors. Trastuzumab duocarmazine, which kills tumor cells by causing DNA damage, induced partial responses in 33% of patients whose tumors were resistant to the approved antibody-drug conjugate trastuzumab emtansine. The drug caused fatigue, neutropenia, pneumonitis, and eye-related side effects.